Can BRAFV600E mutation testing help diagnose high-suspicion thyroid nodules with non-malignant cytology?
When a thyroid nodule looks suspicious on an ultrasound but a standard fine-needle aspiration (FNA) test comes back as benign, doctors face a difficult choice. This situation often happens because the cell sample missed the cancer cells or the cancer was too small to find. Testing for the BRAFV600E mutation can clarify the diagnosis in these specific cases.
What the research says
Research shows that the BRAFV600E mutation is a key marker for papillary thyroid carcinoma, the most common type of thyroid cancer. In a large study of 562 nodules with suspicious ultrasound features but non-malignant cytology, nearly half (49.8%) of the nodules had this mutation. Among those with the mutation, 66.2% were found to be cancer upon surgery, compared to only 12.8% of those without it 36.
The presence of this mutation strongly predicts cancer even when the standard cell test is unclear. Studies indicate that the mutation is found much more often in nodules rated as very high risk on ultrasound (TIRADS 5) than in lower-risk nodules. For example, the mutation appeared in 35.7% of TIRADS 5 nodules versus just 0% in TIRADS 3 nodules 5. This suggests that testing is most useful for nodules that already look dangerous on imaging.
However, experts note that molecular tests like BRAF testing are not always required to decide between watching a nodule or operating. For very small cancers (microcarcinomas) in adults, active surveillance is often a safe option regardless of the test result. Therefore, the test helps refine risk but does not automatically force surgery in every case 4.
What to ask your doctor
- My nodule looks suspicious on ultrasound but my FNA was benign. Would a BRAFV600E mutation test help clarify if I have cancer?
- How does the TIRADS score of my nodule affect the decision to perform a BRAF mutation test?
- If my test is positive for the BRAF mutation, does that mean I must have surgery, or could active surveillance be an option?
- What are the risks and costs of adding a molecular test to my current workup?
- Are there other molecular markers besides BRAF that might be useful if my nodule is indeterminate?
This question is drawn from common patient questions about Gastroenterology and answered using cited medical research. We do not provide individualized advice.